Monday, 20 May 2019

You are here

Vedolizumab Implicated in Exacerbations of SpA in IBD Patients

Beloved by gastroenterologist for treatment of inflammatory bowel disease (IBD), α4β7 integrin receptor vedolizumab (VDZ) has probably caught attention of many rheumatologist since the time it entered the market; largely for what it won't do for inflammatory arthritis.

Many rheumatologists have faced the problem of worsening Spondyloarthritis (SpA) symptoms while CD or UC was well controlled with the biologic in question. This was addressed in a abstract session today.

This was a single-center retrospective and observational study results were presented at this year's EULAR meeting to assess the effects of vedolizumab on joint manifestations in patients with IBD associated SpA.

A total of 171 TNFi experienced patients with IBD (60.8% Crohn's disease (CD) and 39.2 % Ulcerative colitis (UC)) who were treated with VDZ between 2014 and 2017 were observed for average 14 months in the study.  

Active IBD related SpA at the time of VDZ initiation was seen in 2.4% of the patients and 5.8% of the patients had their articular disease in remission.

As a result of VDZ treatment, no clinical benefit to the patients with active disease was observed. In addition VDZ was associated with acute exacerbation of SpA in 6 out of 10 patients who were previously in remission. one case of new onset SpA was reported.

Study concluded that in addition to not being beneficial in IBD-associated SpA, the medication may also be implicated in SpA exacerbations and trigger new onset IBD-associated SpA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Final Guidance on Interchangeability with Biosimilars

The FDA has published an industry guidance document to define interchangeability as regards to biosimilar use in the United States under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)). 

Ustekinumab Effective in Behcet's Disease

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

Polypharmacy Blunts Responses and Ups the Safety Risks

A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.

RheumNowLive On Demand: Development & Use of JAK Inhibitors - Dr. John O'Shea

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

For RA With COPD, Abatacept is Safe

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a large claims-based analysis found.